Pre-injury neuro-psychiatric medication use, alone or in combination with cardiac medications, may affect outcomes in trauma patients
| Autor: | K. Hateley, Daniel S. Eiferman, Andrew N Springer, Steven M. Steinberg, X. M. Mo, Anthony T Gerlach, David C. Evans, Jonathan R. Wisler, Stanislaw P Stawicki, Thomas J Papadimos, Charles H. Cook, Sergio D. Bergese, Claire V. Murphy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry Trauma center lcsh:R Poison control lcsh:Medicine General Medicine Calcium channel blocker Affect (psychology) Cardiac medications Medication regimen neuro-psychiatric medications medication interactions Internal medicine Psychiatric medication mortality and morbidity Injury prevention medicine Intensive care medicine business Beta blocker trauma outcomes |
| Zdroj: | Journal of Postgraduate Medicine, Vol 60, Iss 4, Pp 366-371 (2014) |
| ISSN: | 0972-2823 0022-3859 |
| Popis: | Background: Recent review of older (≥45-years-old) patients admitted to our trauma center showed that more than one-third were using neuro-psychiatric medications (NPMs) prior to their injury-related admission. Previously published data suggests that use of NPMs may increase patients′ risk and severity of injury. We sought to examine the impact of pre-injury NPM use on older trauma patients′ morbidity and mortality. Materials and Methods: Retrospective record review included medication regimen characteristics and NPM use (antidepressants-AD, antipsychotics-AP, anxiolytics-AA). Hospital morbidity, mortality, and 90-day survival were examined. Comparisons included regimens involving NPMs, further focusing on their interactions with various cardiac medications (beta blocker - BB; angiotensin-converting enzyme inhibitor/angiotensin receptor blocker - ACE/ARB; calcium channel blocker - CCB). Results: 712 patient records were reviewed (399 males, mean age 63.5 years, median ISS 8). 245 patients were taking at least 1 NPM: AD (158), AP (35), or AA (108) before injury. There was no effect of NPM monotherapy on hospital mortality. Patients taking ≥3 NPMs had significantly lower 90-day survival compared to patients taking ≤2 NPMs (81% for 3 or more NPMs, 95% for no NPMs, and 89% 1-2 NPMs, P < 0.01). Several AD-cardiac medication (CM) combinations were associated with increased mortality compared to monotherapy with either agent (BB-AD 14.7% mortality versus 7.0% for AD monotherapy or 4.8% BB monotherapy, P < 0.05). Combinations of ACE/ARB-AA were associated with increased mortality compared to ACE/ARB monotherapy (11.5% vs 4.9, P = 0.04). Finally, ACE/ARB-AD co-administration had higher mortality than ACE/ARB monotherapy (13.5% vs 4.9%, P = 0.01). Conclusions: Large proportion of older trauma patients was using pre-injury NPMs. Several regimens involving NPMs and CMs were associated with increased in-hospital mortality. Additionally, use of ≥3 NPMs was associated with lower 90-day survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|